



| CLINICAL MEDICATION POLICY | |
|-----------------------------------|---|
| Policy Name: | Adcetris® (Brentuximab Vedotin) |
| Policy Number: | MP-035-MD-PA |
| Responsible Departments: | Medical Management Medical Policy; Clinical Pharmacy |
| Provider Notice Date: | 06/19/2017 |
| Original Effective Date: | 07/19/2017 |
| Annual Approval Date: | 01/30/2018 |
| Revision Date: | 12/13/2016 |
| Products: | Pennsylvania Medicaid |
| Application: | All participating hospitals and providers |
| Page Number(s): | 1 of 11 |

Disclaimer

Gateway HealthSM (Gateway) clinical medication policy is intended to serve only as a general reference resource regarding payment and coverage for the services described. This policy does not constitute medical advice and is not intended to govern or otherwise influence medical decisions.

POLICY STATEMENT

Gateway HealthSM provides coverage under the medical benefits of the Company's Medicaid products for medically necessary intravenous infusions of Adcetris® (brentuximab vedotin).

This policy is designed to address medical necessity guidelines that are appropriate for the majority of individuals with a particular disease, illness or condition. Each person's unique clinical circumstances warrant individual consideration, based upon review of applicable medical records.

(Current applicable Pennsylvania HealthChoices Agreement Section V. Program Requirements, B. Prior Authorization of Services, 1. General Prior Authorization Requirements.)

DEFINITIONS

Medical Necessity – A service or benefit is medically necessary if it is compensable under the Medical Assistance program and if it meets any one of the following standards:

- The service or benefit will, or is reasonably expected to, prevent the onset of an illness, condition, or disability.
- The service or benefit will, or is reasonably expected to, reduce or ameliorate the physical, mental, or developmental effects of an illness, condition, injury, or disability.
- The service or benefit will assist the patient to achieve or maintain maximum functional capacity in performing daily activities, taking into account both the functional capacity of the patient and those functional capacities that are appropriate for patients of the same age.

PROCEDURES

1. Adcetris is considered eligible for the following conditions when the medical necessity guidelines are met:
 - A. Coverage may be provided when the diagnosis is Hodgkin's disease and the following criteria are met:
 - 1) The member is 18 years of age or older; AND
 - 2) The prescriber is a hematologist/oncologist; AND
 - 3) The member has CD30+ disease; AND
 - 4) The member has failed autologous hematopoietic stem cell transplant (AHSCT); OR
 - 5) The member has failed at least two prior multi-agent chemotherapy regimens when not a candidate for auto-HSCT; OR
 - 6) The medication is being used as consolidation therapy after auto-HSCT for a member at high risk of relapse or disease progression; AND
 - 7) The member is not receiving concurrent treatment with bleomycin; AND
 - 8) The dose does not exceed 1.8 mg/kg (up to 180 mg/dose) and is not administered more frequently than once every three weeks; AND
 - 9) The administration does not exceed 16 cycles when used for consolidation after auto-HSCT
 - B. Coverage may be provided when the diagnosis is Systemic Anaplastic Large Cell Lymphoma (sALCL) and the following criteria are met:
 - 1) The member is 18 years of age or older; AND
 - 2) The prescriber is a hematologist/oncologist; AND
 - 3) The member has CD30+ disease; AND
 - 4) The member has failed at least one prior multi-agent chemotherapy regimen; AND
 - 5) The member is not receiving concurrent treatment with bleomycin; AND
 - 6) The dose does not exceed 1.8 mg/kg (up to 180 mg/dose) and is not administered more frequently than once every three weeks.

2. Contraindications

The safety and effectiveness of Adcetris has not been established in the pediatric population. Clinical trials of Adcetris included only nine pediatric members, and this number is not sufficient to determine whether they respond differently than adult members.

3. Other Contraindications

- A. Members with hypersensitivity to Adcetris or any of its components
- B. Members who have experienced severe motor or sensory neuropathy
- C. Adcetris should not be used in the treatment of lymphocyte predominant Hodgkin lymphoma, unless CD30+ immunophenotype is confirmed
- D. Women who are pregnant or lactating and have not been apprised of the potential hazard to the fetus
- E. Members < 18 years of age (safety and efficacy have not been established)
- F. Adcetris should be used cautiously in members at risk for tumor lysis syndrome
- G. Members with renal and hepatic impairment (safety and efficacy have not been established)
- H. Members that have experienced severe or life-threatening reactions, including any of the following, while receiving Adcetris:
 - 1) Stevens-Johnson Syndrome
 - 2) Severe infusion-related reaction including anaphylaxis
 - 3) Severe neutropenia, not responsive to growth factor
 - 4) Progressive multifocal leukoencephalopathy, related to the use of Adcetris

4. Black Box Warning:

Progressive multifocal leukoencephalopathy (PML): JC virus infection resulting in PML and death can occur in patients receiving Adcetris. JC virus infection resulting in PML and death has been reported in Adcetris treated patients. In addition to Adcetris therapy, other possible contributory factors include prior therapies and underlying disease that may cause immunosuppression. Consider the diagnosis of PML in any patient presenting with new-onset signs and symptoms of central nervous system abnormalities. Evaluation of PML includes, but is not limited to, consultation with a neurologist, brain MRI, and lumbar puncture or brain biopsy. Hold Adcetris dosing for any suspected case of PML and discontinue Adcetris dosing if a diagnosis of PML is confirmed.

5. When Adcetris is not covered

Adcetris is not covered for conditions other than those listed above because the scientific evidence has not been established.

Coverage may be provided for any non-FDA labeled indication or a medically accepted indication that is supported by nationally recognized pharmacy compendia or peer-reviewed medical literature for treatment of the diagnosis for which it is prescribed and will be reviewed on a case-by-case basis to determine medical necessity.

6. Post-payment Audit Statement

The medical record must include documentation that reflects the medical necessity criteria and is subject to audit by Gateway HealthSM at any time pursuant to the terms of your provider agreement.

7. Place of Service

The place of service for the administration of Adcetris is outpatient.

Governing Bodies Approval

Brentuximab vedotin (Adcetris) was approved by the FDA on August 19, 2011, for the treatment of individuals with the following indications:

- 1) Individuals with classical Hodgkin lymphoma after failure of autologous hematopoietic stem cell transplant
- 2) Individuals with classical Hodgkin lymphoma who are not candidates for autologous hematopoietic stem cell transplant and after failure of two prior multi-agent chemotherapy treatments
- 3) Individuals with classical Hodgkin lymphoma at high risk of relapse or progression as post auto-hematopoietic stem cell transplantation consolidation
- 4) Individuals with systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen

CODING REQUIREMENTS

Procedure Codes:

| HCPCS Code | Description |
|------------|--------------------------------------|
| J9042 | Injection, brentuximab vedotin, 1 mg |

Diagnosis Codes:

| ICD-10 Codes | Description |
|--------------|--|
| C81.00 | Nodular lymphocyte predominate Hodgkin lymphoma, unspecified type |
| C81.01 | Nodular lymphocyte predominate Hodgkin lymphoma, lymph nodes of head, face, and neck |
| C81.02 | Nodular lymphocyte predominate Hodgkin lymphoma, intrathoracic lymph nodes |
| C81.03 | Nodular lymphocyte predominate Hodgkin lymphoma, intra-abdominal lymph nodes |
| C81.04 | Nodular lymphocyte predominate Hodgkin lymphoma, lymph nodes of axilla and upper limb |
| C81.05 | Nodular lymphocyte predominate Hodgkin lymphoma, lymph nodes of inguinal region and lower limb |
| C81.06 | Nodular lymphocyte predominate Hodgkin lymphoma, intrapelvic lymph nodes |
| C81.07 | Nodular lymphocyte predominate Hodgkin lymphoma, spleen |
| C81.08 | Nodular lymphocyte predominate Hodgkin lymphoma, lymph nodes of multiple sites |
| C81.09 | Nodular lymphocyte predominate Hodgkin lymphoma, extranodal and solid organ sites |
| C81.10 | Nodular sclerosis classical Hodgkin lymphoma, unspecified site |
| C81.11 | Nodular sclerosis classical Hodgkin lymphoma, lymph nodes of head, neck, and neck |
| C81.12 | Nodular sclerosis classical Hodgkin lymphoma, intrathoracic lymph nodes |

| | |
|--------|---|
| C81.13 | Nodular sclerosis classical Hodgkin lymphoma, intra-abdominal lymph nodes |
| C81.14 | Nodular sclerosis classical Hodgkin lymphoma, lymph nodes of axilla and upper limb |
| C81.15 | Nodular sclerosis classical Hodgkin lymphoma, lymph nodes of inguinal region and lower limb |
| C81.16 | Nodular sclerosis classical Hodgkin lymphoma, intrapelvic lymph nodes |
| C81.17 | Nodular sclerosis classical Hodgkin lymphoma, spleen |
| C81.18 | Nodular sclerosis classical Hodgkin lymphoma, multiple sites |
| C81.19 | Nodular sclerosis classical Hodgkin lymphoma, extranodal and solid organ sites |
| C81.20 | Mixed cellularity classical Hodgkin lymphoma, unspecified site |
| C81.21 | Mixed cellularity classical Hodgkin lymphoma, lymph nodes of head, face and neck |
| C81.22 | Mixed cellularity classical Hodgkin lymphoma, intrathoracic lymph nodes |
| C81.23 | Mixed cellularity classical Hodgkin lymphoma, intra-abdominal lymph nodes |
| C81.24 | Mixed cellularity classical Hodgkin lymphoma, lymph nodes of axilla and upper limb |
| C81.25 | Mixed cellularity classical Hodgkin lymphoma, lymph nodes of inguinal region and lower limb |
| C81.26 | Mixed cellularity classical Hodgkin lymphoma, intrapelvic lymph nodes |
| C81.27 | Mixed cellularity classical Hodgkin lymphoma, spleen |
| C81.28 | Mixed cellularity classical Hodgkin lymphoma, lymph nodes of multiple sites |
| C81.29 | Mixed cellularity classical Hodgkin lymphoma, extranodal and solid organ sites |
| C81.30 | Lymphocyte-depleted classical Hodgkin lymphoma, unspecified site |
| C81.31 | Lymphocyte-depleted classical Hodgkin lymphoma, lymph nodes of head, face and neck |
| C81.32 | Lymphocyte-depleted classical Hodgkin lymphoma, intrathoracic lymph nodes |
| C81.33 | Lymphocyte-depleted classical Hodgkin lymphoma, intra-abdominal lymph nodes |
| C81.34 | Lymphocyte-depleted classical Hodgkin lymphoma, lymph nodes of axilla and upper limb |
| C81.35 | Lymphocyte-depleted classical Hodgkin lymphoma, lymph nodes of inguinal region and lower limb |
| C81.36 | Lymphocyte-depleted classical Hodgkin lymphoma, intrapelvic lymph nodes |
| C81.37 | Lymphocyte-depleted classical Hodgkin lymphoma, spleen |
| C81.38 | Lymphocyte-depleted classical Hodgkin lymphoma, lymph nodes of multiple sites |
| C81.39 | Lymphocyte-depleted classical Hodgkin lymphoma, extranodal and solid organ sites |
| C81.40 | Lymphocyte-rich classical Hodgkin lymphoma, unspecified |
| C81.41 | Lymphocyte-rich classical Hodgkin lymphoma, lymph nodes of head, face and neck |
| C81.42 | Lymphocyte-rich classical Hodgkin lymphoma, intrathoracic lymph nodes |
| C81.43 | Lymphocyte-rich classical Hodgkin lymphoma, intra-abdominal lymph nodes |
| C81.44 | Lymphocyte-rich classical Hodgkin lymphoma, lymph nodes of axilla and upper limb |

| | |
|--------|---|
| C81.45 | Lymphocyte-rich classical Hodgkin lymphoma, lymph nodes of inguinal region and lower limb |
| C81.46 | Lymphocyte-rich classical Hodgkin lymphoma, intrapelvic lymph nodes |
| C81.47 | Lymphocyte-rich classical Hodgkin lymphoma, spleen |
| C81.48 | Lymphocyte-rich classical Hodgkin lymphoma, lymph nodes of multiple sites |
| C81.49 | Lymphocyte-rich classical Hodgkin lymphoma, extranodal and solid organ sites |
| C81.70 | Other classical Hodgkin lymphoma, unspecified site |
| C81.71 | Other classical Hodgkin lymphoma, lymph nodes of head, face and neck |
| C81.72 | Other classical Hodgkin lymphoma, intrathoracic lymph nodes |
| C81.73 | Other classical Hodgkin lymphoma, intra-abdominal lymph nodes |
| C81.74 | Other classical Hodgkin lymphoma, lymph nodes of axilla and upper limb |
| C81.75 | Other classical Hodgkin lymphoma, lymph nodes of inguinal region and lower limb |
| C81.76 | Other classical Hodgkin lymphoma, intrapelvic lymph nodes |
| C81.77 | Other classical Hodgkin lymphoma, spleen |
| C81.78 | Other classical Hodgkin lymphoma, lymph nodes of multiple sites |
| C81.79 | Other classical Hodgkin lymphoma, extranodal and solid organ sites |
| C81.90 | Hodgkin lymphoma, unspecified, unspecified site |
| C81.91 | Hodgkin lymphoma, unspecified, lymph nodes of head, face and neck |
| C81.92 | Hodgkin lymphoma, unspecified, intrathoracic lymph nodes |
| C81.93 | Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes |
| C81.94 | Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb |
| C81.95 | Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb |
| C81.96 | Hodgkin lymphoma, unspecified, intrapelvic lymph nodes |
| C81.97 | Hodgkin lymphoma, unspecified, spleen |
| C81.98 | Hodgkin lymphoma, unspecified, lymph nodes of multiple sites |
| C81.99 | Hodgkin lymphoma, unspecified, extranodal and solid organ sites |
| C82.50 | Diffuse follicle center lymphoma, unspecified site |
| C82.51 | Diffuse follicle center lymphoma, lymph nodes of head, face and neck |
| C82.52 | Diffuse follicle center lymphoma, intrathoracic lymph nodes |
| C82.53 | Diffuse follicle center lymphoma, intra-abdominal lymph nodes |
| C82.54 | Diffuse follicle center lymphoma, lymph nodes of axilla and upper limb |
| C82.55 | Diffuse follicle center lymphoma, lymph nodes of inguinal region and lower limb |
| C82.56 | Diffuse follicle center lymphoma, intrapelvic lymph nodes |
| C82.57 | Diffuse follicle center lymphoma, spleen |
| C82.58 | Diffuse follicle center lymphoma, lymph nodes of multiple sites |
| C82.59 | Diffuse follicle center lymphoma, extranodal and solid organ sites |
| C84.A0 | Cutaneous T-cell lymphoma, unspecified, unspecified site |
| C84.A1 | Cutaneous T-cell lymphoma, unspecified, unspecified lymph nodes of head, face and neck |
| C84.A2 | Cutaneous T-cell lymphoma, unspecified, intrathoracic lymph nodes |
| C84.A3 | Cutaneous T-cell lymphoma, unspecified, intra-abdominal lymph nodes |

| | |
|--------|--|
| C84.A4 | Cutaneous T-cell lymphoma, unspecified, lymph nodes of axilla and upper limb |
| C84.A5 | Cutaneous T-cell lymphoma, unspecified, lymph nodes of inguinal region and lower limb |
| C84.A6 | Cutaneous T-cell lymphoma, unspecified, intrapelvic lymph nodes |
| C84.A7 | Cutaneous T-cell lymphoma, unspecified, spleen |
| C84.A8 | Cutaneous T-cell lymphoma, unspecified, lymph nodes of multiple sites |
| C84.A9 | Cutaneous T-cell lymphoma, unspecified, extranodal and solid organ sites |
| C84.Z0 | Other mature T/NK-cell lymphomas, unspecified site |
| C84.Z1 | Other mature T/NK-cell lymphomas, lymph nodes of head, face and neck |
| C84.Z2 | Other mature T/NK-cell lymphomas, intrathoracic lymph nodes |
| C84.Z3 | Other mature T/NK-cell lymphomas, intra-abdominal lymph nodes |
| C84.Z4 | Other mature T/NK-cell lymphomas, lymph nodes of axilla and upper limb |
| C84.Z5 | Other mature T/NK-cell lymphomas, lymph nodes of inguinal region and lower limb |
| C84.Z6 | Other mature T/NK-cell lymphomas, intrapelvic lymph nodes |
| C84.Z7 | Other mature T/NK-cell lymphomas, spleen |
| C84.Z8 | Other mature T/NK-cell lymphomas, lymph nodes of multiple sites |
| C84.Z9 | Other mature T/NK-cell lymphomas, extranodal and solid organ sites |
| C84.90 | Mature T/NK-cell lymphomas, unspecified, unspecified site |
| C84.91 | Mature T/NK-cell lymphomas, unspecified, lymph nodes of head, face and neck |
| C84.92 | Mature T/NK-cell lymphomas, unspecified, intrathoracic lymph nodes |
| C84.93 | Mature T/NK-cell lymphomas, unspecified, intra-abdominal lymph nodes |
| C84.94 | Mature T/NK-cell lymphomas, unspecified, lymph nodes of axilla and upper limb |
| C84.95 | Mature T/NK-cell lymphomas, unspecified, lymph nodes of inguinal region and lower limb |
| C84.96 | Mature T/NK-cell lymphomas, unspecified, intrapelvic lymph nodes |
| C84.97 | Mature T/NK-cell lymphomas, unspecified, spleen |
| C84.98 | Mature T/NK-cell lymphomas, unspecified, lymph nodes of multiple sites |
| C84.99 | Mature T/NK-cell lymphomas, unspecified, extranodal and solid organ sites |
| C85.10 | Unspecified B-cell lymphoma, unspecified site |
| C85.11 | Unspecified B-cell lymphoma, lymph nodes of head, face and neck |
| C85.12 | Unspecified B-cell lymphoma, intrathoracic lymph nodes |
| C85.13 | Unspecified B-cell lymphoma, intra-abdominal lymph nodes |
| C85.14 | Unspecified B-cell lymphoma, lymph nodes of axilla and upper limb |
| C85.15 | Unspecified B-cell lymphoma, lymph nodes of inguinal region and lower limb |
| C85.16 | Unspecified B-cell lymphoma, intrapelvic lymph nodes |
| C85.17 | Unspecified B-cell lymphoma, spleen |
| C85.18 | Unspecified B-cell lymphoma, lymph nodes of multiple sites |
| C85.19 | Unspecified B-cell lymphoma, extranodal and solid organ sites |
| C85.20 | Mediastinal (thymic) large B-cell lymphoma, unspecified site |
| C85.21 | Mediastinal (thymic) large B-cell lymphoma, lymph nodes of head, face and neck |
| C85.22 | Mediastinal (thymic) large B-cell lymphoma, intrathoracic lymph nodes |

| | |
|--------|--|
| C85.23 | Mediastinal (thymic) large B-cell lymphoma, intra-abdominal lymph nodes |
| C85.24 | Mediastinal (thymic) large B-cell lymphoma, lymph nodes of axilla and upper limb |
| C85.25 | Mediastinal (thymic) large B-cell lymphoma, lymph nodes of inguinal region and lower limb |
| C85.26 | Mediastinal (thymic) large B-cell lymphoma, intrapelvic lymph nodes |
| C85.27 | Mediastinal (thymic) large B-cell lymphoma, spleen |
| C85.28 | Mediastinal (thymic) large B-cell lymphoma, lymph nodes of multiple sites |
| C85.29 | Mediastinal (thymic) large B-cell lymphoma, extranodal and solid organ sites |
| C85.80 | Other specified types of non-Hodgkin lymphoma, unspecified site |
| C85.81 | Other specified types of non-Hodgkin lymphoma, lymph nodes of head, face and neck |
| C85.82 | Other specified types of non-Hodgkin lymphoma, intrathoracic lymph nodes |
| C85.83 | Other specified types of non-Hodgkin lymphoma, intra-abdominal lymph nodes |
| C85.84 | Other specified types of non-Hodgkin lymphoma, lymph nodes of axilla and upper limb |
| C85.85 | Other specified types of non-Hodgkin lymphoma, lymph nodes of inguinal region and lower limb |
| C85.86 | Other specified types of non-Hodgkin lymphoma, intrapelvic lymph nodes |
| C85.87 | Other specified types of non-Hodgkin lymphoma, spleen |
| C85.88 | Other specified types of non-Hodgkin lymphoma, lymph nodes of multiple sites |
| C85.89 | Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites |
| C85.90 | Non-Hodgkin lymphoma, unspecified, unspecified site |
| C85.91 | Non-Hodgkin lymphoma, unspecified, lymph nodes of head, neck and face |
| C85.92 | Non-Hodgkin lymphoma, unspecified, intrathoracic lymph nodes |
| C85.93 | Non-Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes |
| C85.94 | Non-Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb |
| C85.95 | Non-Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb |
| C85.96 | Non-Hodgkin lymphoma, unspecified, intrapelvic lymph nodes |
| C85.97 | Non-Hodgkin lymphoma, unspecified, spleen |
| C85.98 | Non-Hodgkin lymphoma, unspecified, lymph nodes of multiple sites |
| C85.99 | Non-Hodgkin lymphoma, unspecified, extranodal and solid organ sites |
| C83.00 | Small cell B-cell lymphoma, unspecified |
| C83.01 | Small cell B-cell lymphoma, lymph nodes of head, face and neck |
| C83.02 | Small cell B-cell lymphoma, intrathoracic lymph nodes |
| C83.03 | Small cell B-cell lymphoma, intra-abdominal lymph nodes |
| C83.04 | Small cell B-cell lymphoma, lymph nodes of axilla and upper limb |
| C83.05 | Small cell B-cell lymphoma, lymph nodes of inguinal region and lower limb |
| C83.06 | Small cell B-cell lymphoma, intrapelvic lymph nodes |
| C83.07 | Small cell B-cell lymphoma, spleen |
| C83.08 | Small cell B-cell lymphoma, lymph nodes of multiple sites |
| C83.09 | Small cell B-cell lymphoma, extranodal and solid organ sites |

| | |
|--------|---|
| C83.80 | Other non-follicle lymphoma, unspecified site |
| C83.81 | Other non-follicle lymphoma, lymph nodes of head, face and neck |
| C83.82 | Other non-follicle lymphoma, intrathoracic lymph nodes |
| C83.83 | Other non-follicle lymphoma, intra-abdominal lymph nodes |
| C83.84 | Other non-follicle lymphoma, lymph nodes of axilla and upper limb |
| C83.85 | Other non-follicle lymphoma, lymph nodes of inguinal regional and lower limb |
| C83.86 | Other non-follicle lymphoma, intrapelvic lymph nodes |
| C83.87 | Other non-follicle lymphoma, spleen |
| C83.88 | Other non-follicle lymphoma, lymph nodes of multiple sites |
| C83.89 | Other non-follicle lymphoma, extranodal and solid organ sites |
| C83.90 | Non-follicular (diffuse) lymphoma, unspecified, unspecified site |
| C83.91 | Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of head, face and neck |
| C83.92 | Non-follicular (diffuse) lymphoma, unspecified, intrathoracic lymph nodes |
| C83.93 | Non-follicular (diffuse) lymphoma, unspecified, intra-abdominal lymph nodes |
| C83.94 | Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of axilla and upper limb |
| C83.95 | Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of inguinal region and lower limb |
| C83.96 | Non-follicular (diffuse) lymphoma, unspecified, intrapelvic lymph nodes |
| C83.97 | Non-follicular (diffuse) lymphoma, unspecified, spleen |
| C83.98 | Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of multiple sites |
| C83.99 | Non-follicular (diffuse) lymphoma, unspecified, extranodal and solid organ sites |
| C86.5 | Angioimmunoblastic T-cell lymphoma |
| C84.40 | Peripheral T-cell lymphoma, not classified, unspecified site |
| C84.41 | Peripheral T-cell lymphoma, not classified, lymph nodes of head, face and neck |
| C84.42 | Peripheral T-cell lymphoma, not classified, intrathoracic lymph nodes |
| C84.43 | Peripheral T-cell lymphoma, not classified, intra-abdominal lymph nodes |
| C84.44 | Peripheral T-cell lymphoma, not classified, lymph nodes of axilla and upper limb |
| C84.45 | Peripheral T-cell lymphoma, not classified, lymph nodes of inguinal region and lower limb |
| C84.46 | Peripheral T-cell lymphoma, not classified, intrapelvic lymph nodes |
| C84.47 | Peripheral T-cell lymphoma, not classified, spleen |
| C84.48 | Peripheral T-cell lymphoma, not classified, lymph nodes of multiple sites |
| C84.49 | Peripheral T-cell lymphoma, not classified, extranodal and solid organ sites |
| C84.60 | Anaplastic large cell lymphoma, ALK-positive, unspecified site |
| C84.61 | Anaplastic large cell lymphoma, ALK-positive, lymph nodes of head, face and neck |
| C84.62 | Anaplastic large cell lymphoma, ALK-positive, intrathoracic lymph nodes |
| C84.63 | Anaplastic large cell lymphoma, ALK-positive, intra-abdominal lymph nodes |
| C84.64 | Anaplastic large cell lymphoma, ALK-positive, lymph nodes of axilla and upper limb |

| | |
|--------|---|
| C84.65 | Anaplastic large cell lymphoma, ALK-positive, lymph nodes of inguinal region and lower limb |
| C84.66 | Anaplastic large cell lymphoma, ALK-positive, intrapelvic lymph nodes |
| C84.67 | Anaplastic large cell lymphoma, ALK-positive, spleen |
| C84.68 | Anaplastic large cell lymphoma, ALK-positive, lymph nodes of multiple sites |
| C84.69 | Anaplastic large cell lymphoma, ALK-positive, extranodal and solid organ sites |
| C84.70 | Anaplastic large cell lymphoma, ALK-negative, unspecified site |
| C84.71 | Anaplastic large cell lymphoma, ALK-negative, lymph nodes of head, face and neck |
| C84.72 | Anaplastic large cell lymphoma, ALK-negative, intrathoracic lymph nodes |
| C84.73 | Anaplastic large cell lymphoma, ALK-negative, intra-abdominal lymph nodes |
| C84.74 | Anaplastic large cell lymphoma, ALK-negative, lymph nodes of axilla and upper limb |
| C84.75 | Anaplastic large cell lymphoma, ALK-negative, lymph nodes of inguinal region and lower limb |
| C84.76 | Anaplastic large cell lymphoma, ALK-negative, intrapelvic lymph nodes |
| C84.77 | Anaplastic large cell lymphoma, ALK-negative, spleen |
| C84.78 | Anaplastic large cell lymphoma, ALK-negative, lymph nodes of multiple sites |
| C84.79 | Anaplastic large cell lymphoma, ALK-negative, extranodal and solid organ sites |

REIMBURSEMENT

Participating facilities will be reimbursed per their Gateway HealthSM contract.

POLICY SOURCE(S)

ADCETRIS® [package insert]. Seattle Genetics, Inc. Bothell, WA. August 2015. Available at: <http://www.adcetris.com/pdf/ADCETRIS-brentuximab-vedotin-Prescribing-Information.pdf>.

Chen RW, Gopal AK, Smith SE, et al. Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL). ASCO Meeting Abstracts 2011; 29(15_suppl):8031. Available at: <http://meetinglibrary.asco.org/content/76520-102>.

NCCN Guidelines Version 2.2014 Hodgkin Lymphoma. National Comprehensive Cancer Network, Inc. 2.2012. Available at: http://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf.

National Comprehensive Cancer Network – Drugs & Biologics Compendium. Brentuximab vedotin. Available at: http://www.nccn.org/professionals/drug_compendium/MatrixGenerator/PrintMatrix.aspx?AID=374.

Younes A, Bartlett N, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Eng J Med 2010; 363:1812-1821. November 4 2010. DOI: 10.1056/NEJMoa1002965. Available at: <http://www.nejm.org/doi/full/10.1056/NEJMoa1002965>.

Policy History

| Date | Policy Information |
|------------|--|
| 08/26/2016 | Initial policy developed |
| 12/01/2016 | Provider effective date |
| 12/13/2016 | Revisions: Annual Review, updated indications and dosage, and updated references Criteria Changes: <ul style="list-style-type: none">• Age criteria deletion for Hodgkin lymphoma and sALCL- <i>"The patient is not aged 65 years or older"</i>;• Disease type addition for Hodgkin lymphoma and sALCL- <i>The member has CD30+ DISEASE;</i>• Interaction with other drug for Hodgkin lymphoma and sALCL- <i>The member is not receiving concurrent treatment with bleomycin;</i>• Removal of CD30+ Cutaneous Anaplastic Large Cell Lymphoma condition. |
| 05/17/2017 | QI/UM approval |
| 07/19/2017 | Provider effective date |